Studies suggest immunotherapy adds punch to earlier attempts

December 2, 2018, NYU Langone Health

New drugs that harness the body's immune system to destroy cancer cells appear to increase the effectiveness of later drug therapies for non-Hodgkin and Hodgkin lymphoma patients, new research suggests. This happens, scientists say, even for repeat drug therapies whose initial attempts failed to stop or reverse the disease.

Researchers at NYU School of Medicine and its Perlmutter Cancer Center who led the pair of new studies, both presented Dec. 1 at the annual meeting of the American Society of Hematology in San Diego, say their findings are the first multicenter data to show that even when "second-line" immunotherapy fails to control the disease, it likely "sensitizes" to better respond to future use of drugs that did not work very well the first time. Few treatment options exist, researchers say, for relapsing non-Hodgkin lymphoma .

Both studies involved a review of the medical records of men and women treated between 2012 and 2018 at 17 medical centers in the United States and Canada, all of whom failed to have a lasting response to initial , including stem cell transplantations and/or standard chemotherapy with or without brentuximab vedotin (marketed as Adcentris), a that primes the immune system and aids chemotherapy. Subsequent therapy with so-called checkpoint-blockade inhibitors, such as ipilimumab (Yervoy) and nivolumab (Opdivo), were also not successful in controlling cancer spread. When effective, such drugs work by turning off inhibitory switches, or "checkpoints," on immune T cell surfaces, which are known to prevent the immune system from identifying and attacking tumor cells.

However, in 59 patients with non-Hodgkin lymphoma, 30 responded to additional chemotherapy or other drug treatment after having received checkpoint inhibitors. Of the 29 patients still alive and receiving therapy, 16 have not seen any cancer spread.

In 112 patients with Hodgkin lymphoma who received checkpoint blockade therapy, 81 needed some form of follow-up drug treatment. Sixty-six remain alive, and 30 have not experienced any worsening of their disease.

"These are very high success rates for post-checkpoint blockade therapy, especially in patients for whom several drug therapies have failed, including the same or similar drugs used again after checkpoint therapy," says senior study investigator and hematologist-oncologist Catherine Diefenbach, MD.

Diefenbach, an assistant professor at NYU Langone and clinical director of lymphoma program services at its Perlmutter Cancer Center, cautioned that prospective clinical trials, in which patients are closely monitored from the start of their therapy over long periods of time, are needed before researchers can conclude whether or not checkpoint blockade therapy was responsible for the greater effectiveness of subsequent treatments.

"What our current study strongly suggests, however, is that the benefits of checkpoint blockade therapy are not limited to their initial ability to stop the disease," says lead study investigator Nicole Carreau, MD, a postdoctoral hematology and oncology fellow at NYU Langone and Perlmutter.

Both kinds of lymphoma are cancers of immune cells that help the body fight off infections and other diseases, says Carreau. Non-Hodgkin lymphoma is more common in the United States, with more than 72,000 new cases diagnosed each year (with more than 20,000 deaths from the disease), compared with about 8,500 for Hodgkin (and over 1,000 deaths).

Explore further: Combination immune therapy shows promise against Hodgkin lymphoma

More information: These presentations at the American Society of Hematology Annual Meeting are abstracts #93 and #1626. Abstract #93 is titled Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy. Abstract #1626 is titled Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy.

Related Stories

Combination immune therapy shows promise against Hodgkin lymphoma

December 5, 2016
The combination of two new drugs that harness the body's immune system is safe and effective, destroying most cancer cells in 64 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early-phase ...

Immunotherapy agent yields full and partial remissions in aggressive non-Hodgkin lymphomas

December 6, 2016
An immunotherapy drug able to induce lasting remissions in classical Hodgkin lymphoma may be equally effective in patients with either of two rare, aggressive forms of non-Hodgkin lymphoma, results from a small case series ...

Engineered cell therapy rejected for aggressive adult lymphoma on NHS in England

September 19, 2018
A cancer immunotherapy has been provisionally rejected as a treatment for some adults with an aggressive type of non-Hodgkin lymphoma on the NHS in England.

New treatment for non-Hodgkin lymphoma approved

August 9, 2018
(HealthDay)—Poteligeo (mogamulizumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with two types of non-Hodgkin lymphoma.

Five-year survival data: Brentuximab vedotin may be curative in some with Hodgkin lymphoma

July 18, 2016
Five-year survival data published online today in Blood, the Journal of the American Society of Hematology (ASH), suggest that the targeted therapy brentuximab vedotin may have cured some Hodgkin lymphoma patients whose disease ...

Having HIV and chronic HBV/HCV coinfection may increase cancer risk

October 17, 2016
In HIV-infected patients receiving antiretroviral therapy (ART), chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) coinfection is associated with an increased risk for non-Hodgkin's lymphoma. The findings are published ...

Recommended for you

Two ways cancer resists treatment are actually connected, with one activating the other

December 18, 2018
Drugs that target BRAF and MEK in cancer have shown promise in treating a subset of melanoma that carries a mutation in the BRAF gene, but drug resistance usually emerges, reversing the benefit of these drugs and limiting ...

Gene variant found in brain complicit in MS onset

December 18, 2018
Multiple sclerosis (MS) is an autoimmune disease affecting the function of the central nervous system. Up to now, most of the 230 genetic variants associated with the disease have been linked to changes in immune cells. However, ...

Gut microbiome regulates the intestinal immune system, researchers find

December 18, 2018
Scientist have long known that bacteria in the intestines, also known as the microbiome, perform a variety of useful functions for their hosts, such as breaking down dietary fiber in the digestive process and making vitamins ...

How a single faulty gene can lead to lupus

December 18, 2018
A research team at the Academy of Immunology and Microbiology, within the Institute for Basic Science (IBS) & Pohang University of Science and Technology (POSTECH) in South Korea has discovered the role of a key gene involved ...

HPV discovery raises hope for new cervical cancer treatments

December 18, 2018
Researchers at the University of Virginia School of Medicine have made a discovery about human papillomavirus (HPV) that could lead to new treatments for cervical cancer and other cancers caused by the virus.

Vaccine, checkpoint drugs combination shows promise for pancreatic cancers

December 18, 2018
Researchers at the Johns Hopkins Kimmel Cancer Center discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, demonstrating a possible pathway for treatment of people ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.